Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1 to 15 of 85 results for perfusion

  1. Machine perfusion systems and cold static storage of kidneys from deceased donors (TA165)

    Evidence-based recommendations on machine perfusion systems and cold static storage of kidneys from deceased donors.

    Technology appraisal guidance
    Published
    28 January 2009
    View recommendations

    Sections for TA165

  2. XVIVO hypothermic perfusion of the DCD heart

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  3. Ex-situ machine perfusion for extracorporeal preservation of lungs (ex-vivo lung perfusion) for transplant (HTG580)

    Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of lungs for transplant. This involves using a machine to deliver an oxygenated solution to a donor lung and keep it at normal body temperature until it can be transplanted.

    HealthTech guidance
    Published
    26 May 2021
    View recommendations

    Sections for HTG580

  4. Perfusion-induced systemic hyperthermia for the treatment of advanced lung cancer

    Topic prioritisation

    Interventional procedures guidance
    Topic prioritisation

  5. Myocardial perfusion scintigraphy for the diagnosis and management of angina and myocardial infarction (TA73)

    Evidence-based recommendations on myocardial perfusion scintigraphy for diagnosing and managing angina and myocardial infarction in adults.

    Technology appraisal guidance
    Last updated
    1 July 2011
    View recommendations

    Sections for TA73

  6. Ex-situ machine perfusion for extracorporeal preservation of livers for transplantation (HTG496)

    Evidence-based recommendations on ex-situ machine perfusion for extracorporeal preservation of livers for transplantation in people of all ages. This involves using a machine to give an oxygenated solution to the donor liver until it is transplanted.

    HealthTech guidance
    Published
    16 January 2019
    View recommendations

    Sections for HTG496

  7. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver

    In development Reference number: GID-HTG10870 Expected publication date:  15 October 2026

    HealthTech guidance
    In development

  8. Ex-situ machine perfusion devices to preserve deceased donor livers for transplantation

    In development Reference number: GID-HTG10874 Expected publication date:  20 August 2026

    HealthTech guidance
    In development

  9. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver: interventional procedure consultation

    We are listening to your views on this HealthTech guidance. Comments close 7 July 2026.

    In consultation

  10. Extracorporeal whole liver perfusion for acute liver failure (HTG573)

    Evidence-based recommendations on extracorporeal whole liver perfusion for acute liver failure. This involves blood being diverted to a whole liver (perfusion) outside the body and returned to the patient.

    HealthTech guidance
    Published
    31 March 2021
    View recommendations

    Sections for HTG573

  11. Ex-situ machine perfusion devices for lung transplants

    In development Reference number: GID-HTE10084 Expected publication date:  21 October 2026

    In development

  12. Ex-situ machine perfusion devices for lung transplants

    In development Reference number: GID-HTG10878 Expected publication date:  21 October 2026

    HealthTech guidance
    In development

  13. In-situ abdominal normothermic regional perfusion to preserve donor livers during retrieval for transplantation after controlled circulatory death: interventional procedure consultation

    We are listening to your views on this HealthTech guidance. Comments close 28 July 2026.

    In consultation

  14. Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver (HTG575)

    Evidence-based recommendations on melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver. This involves diverting the blood flow from the liver to the rest of the body while the drug is delivered directly into the liver.

    HealthTech guidance
    Published
    21 April 2021
    View recommendations

    Sections for HTG575

  15. In-situ abdominal normothermic regional perfusion to preserve donor livers during retrieval for transplantation after controlled circulatory death

    In development Reference number: GID-HTG10880 Expected publication date:  19 November 2026

    HealthTech guidance
    In development